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(12%), complexes that are highly prevalent worldwide 
among  S. aureus strains  isolated from humans colonized or 
infected with  S. aureus. DNA microarray profiles showed a 
wide variety of genes encoding antimicrobial resistance and 
virulence factors such as various leukocidins, haemolysins, 
enterotoxins, exfoliative toxins, toxic shock syndrome toxin, 
as well as genes involved in adhesion and immune evasion. 
 Conclusions: While a large number of strains exhibited resis-
tance to one or several antimicrobial agents, methicillin-re-
sistant  S. aureus was found at a low prevalence of 3% (n = 2) 
only. The two methicillin-resistant  S. aureus isolates were as-
signed to CC152/t355 (SCC mec V) and CC5/t001 (SCC mec I). 
This is the first study to genetically characterize  S. aureus iso-
lates in CF patients in Austria.  © 2015 S. Karger AG, Basel 
 Introduction 
 Cystic fibrosis (CF) represents the most prevalent life-
limiting inherited disease in Caucasian populations  [1] . 
While all organs expressing the cystic fibrosis transmem-
brane conductance regulator (including secretory cells, 
airways, liver, pancreas, and the reproductive tract) can 
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 Abstract 
 Background: Cystic fibrosis (CF) is the most common life-
limiting inherited disease in Caucasian populations. While 
pathological changes can be seen in various organs, morbid-
ity and mortality are mainly related to the respiratory tract, 
with patients suffering from chronic bronchopulmonary in-
fections with characteristic pathogens including  Staphylo-
coccus aureus.  Objectives: To date, there is only very limited 
data on the genetic and phenotypic characteristics of  S. au-
reus  in CF patients. Therefore, in our study, we characterized 
58  S. aureus  isolates collected from CF patients in Austria by 
 spa  typing, DNA microarray profiling, as well as antimicro-
bial susceptibility testing in order to determine common ge-
nomic and antimicrobial resistance features. The tested 
strain collection exhibited high genomic diversity.  Results: 
The 58 isolates were assigned to 16 clonal complexes and 48 
 spa  types and differed greatly regarding their virulence and 
resistance gene profiles. The predominant clonal complexes 
were MLST CC30 (22%), CC15 (16%), CC45 (14%), and CC5 
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be affected, the most severe pathological changes are usu-
ally seen in the respiratory tract  [2] . Airway pathology is 
characterized by obstruction, inflammation, and severe 
recurrent and/or chronic bacterial infections. One of the 
most prevalent organisms that can be detected in CF pa-
tients is  Staphylococcus aureus,  which was reported to 
represent one of the first pathogens infecting the airways 
of CF patients and persisting for months or even years  [3] . 
During the last decades, infections with both methicillin-
susceptible (MSSA) and methicillin-resistant  S. aureus 
(MRSA) have increased considerably in CF patients in the 
United States. Prevalence of  S. aureus in CF patients’ re-
spiratory cultures increased from 29% in 1992 to 69% in 
2012, with the prevalence of MRSA increasing from 9% 
in 2002 to 25% in 2012  [4] . The same trend can be ob-
served in European countries, whereas CF centres here 
report a lower rate of MSSA and MRSA in CF patients  [5, 
6] . Beside asymptomatic colonization of a patient, MSSA 
and MRSA can provoke a broad spectrum of infections, 
such as local infections up to endocarditis, pneumonia or 
sepsis. There are several publications reporting that 
MRSA-positive CF patients exhibit more complications, 
such as an increased hospitalization rate, an accelerated 
decline in lung function and an increased mortality rate 
 [7, 8] . Effective treatment of both MSSA and MRSA infec-
tions represents a major challenge, as  S. aureus exhibits a 
huge repertoire of different resistance and virulence fac-
tors  [9] .
 To date, it is still poorly understood which virulence 
factors are crucial in the pathogenesis of  S. aureus  infec-
tions in CF patients, and there is only little information 
on genomic and antimicrobial features of these strains. 
Microbiologic laboratories offer a number of different 
molecular typing methods, such as  spa typing or more 
recently microarray techniques, which allow a more de-
tailed view on the epidemiological as well as the genetic 
background of the investigated strains. Therefore, in this 
study, 58 isolates collected from 51 CF patients in Austria 
were  spa  typed, and resistance and virulence gene profiles 
were investigated by DNA microarray analysis in order to 
gain new insights into the genomic and antimicrobial 
characteristics of  S. aureus  strains in CF patients.
 Materials and Methods 
 Bacterial Strains 
 All  S. aureus isolates included in this study were investigated at 
the CF Laboratory at the Institute of Hygiene, Microbiology and 
Environmental Medicine, Medical University of Graz, Austria. 
Samples originated from 51 CF patients and were collected over a 
period of 1 year in the CF centre at the Respiratory and Allergic Dis-
ease Division, Department of Paediatrics and Adolescent Medicine, 
Medical University of Graz. A total of 23 (45%) patients were male 
and 28 (55%) female. The patients’ age ranged from 1 to 41 years, 
with a median age of 16 years. Samples included sputa (n = 46), 
throat swabs (n = 10), and bronchoalveolar lavage fluids (n = 2).
 Species Identification and Antimicrobial Susceptibility Testing 
 S. aureus isolates were identified using a VITEK 2 (bioMérieux, 
Marcy l’Etoile, France) or MALDI-TOF MS instrument (Axima TM 
Assurance, Shimadzu, Japan). Susceptibility testing was performed 
using both disk diffusion (Becton Dickinson, Heidelberg, Germa-
ny), according to the guidelines of the European Committee of An-
timicrobial Susceptibility Testing, evaluating the susceptibility to 
penicillin (1 μg), cefoxitin (30 μg), erythromycin (15 μg), clindamy-
cin (2 μg), gentamicin (10 μg), and trimethoprim/sulfamethoxazole 
(1.25/23.75 μg), and the VITEK 2 instrument (using the P580 card). 
Results were interpreted according to the guidelines of the Euro-
pean Committee of Antimicrobial Susceptibility Testing  [10] .  S. 
aureus with identical resistance phenotypes that had been isolated 
from the same patient were excluded from the study.
 Molecular Characterization by spa Typing and DNA 
Microarray 
 spa  typing is a widely used technique for subtyping  S. aureus 
for epidemiological surveillance in hospital and community set-
tings. The  spa typing method is based on sequencing of the poly-
morphic X region of the protein A gene  (spa) , present in almost all 
strains of  S. aureus.  We extracted DNA and performed s pa  typing 
as described by Ruppitsch et al.  [11] . StaphyType DNA microarray 
(Clondiag Chip Technologies, Jena, Germany) was used according 
to the manufacturer’s instructions to assign isolates to clonal com-
plexes and to generate virulence and resistance gene profiles. This 
microarray system detects the presence/absence of genes confer-
ring resistance to antimicrobial agents, as well as genes encoding 
for various virulence factors such as haemolysins, leukocidins, en-
terotoxins, and exfoliative toxins. In order to visualize the diver-
sity of DNA microarray patterns, as well as strain relatedness, hy-
bridization patterns were analysed using the SplitsTree software 
(www.splitstree.org), designed to compute unrooted phylogenetic 
networks from molecular sequence data  [12] . DNA microarray 
gene profiles were converted to ‘sequence-like’ strings of informa-
tion as previously described  [13] .
 Ethics Statement 
 No ethical clearance was necessary, as the strains were isolated 
for diagnostic purposes and the patients were informed and con-
sented in writing to the anonymized use of the isolates for study 
purposes.
 Results 
 As 6 samples harboured 2 (n = 5) or 3 (n = 1)  S. aureus 
isolates with different resistance phenotypes, a total of 58 
 S. aureus  isolates collected from 51 CF patients were in-
cluded in the study. Among the investigated isolates, we 
frequently detected isolates resistant to one or more anti-
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biotic agents, including 2 (3%) MRSA strains ( table 1 ). A 
high number of strains showed resistance to penicillin 
(84%), erythromycin (41%), trimethoprim (14%), and 
gentamicin (10%), and 31% of the isolates exhibited in-
ducible clindamycin resistance. The 58  S. aureus isolates 
were assigned to 16 MLST clonal complexes and 48 dif-
ferent  spa types ( fig. 1 ). The most common clonal com-
plexes were CC30 (22%), CC15 (16%), CC45 (14%), and 
CC5 (12%). While most  spa  types were unique, t002, t084, 
and t521 were found in 3 patients each, and t005, t9536, 
t021, and t335 were found in 2 patients each. The 2 MRSA 
isolates were assigned to CC152/t355 (SCC mec V) and 
CC5/t001 (SCC mec I).
 The results of the DNA microarray showed an overall 
high genomic diversity among the  S. aureus isolates, 
which is depicted in the SplitsTree ( fig. 2 ). While  S. au-
reus of the same clonal complex formed clusters, all iso-
lates exhibited unique DNA microarray patterns and are 
thus representing different strains.
 Regarding resistance genes (online suppl. table 1; see 
www.karger.com/doi/10.1159/000377707 for all online 
suppl. material), 86% of the  S. aureus isolates exhibited 
 blaZ/R/I , involved in resistance to penicillin, and 3% har-
boured the  mecA gene conferring resistance to methicil-
lin. Genes involved in resistance to macrolides, lincos-
amides, and streptogramin were found in 11 (19%;  ermA ), 
1 (2%;  ermB ), and 6 (10%;  ermC ) of the isolates. Concern-
ing resistance to aminoglycosides, 11 isolates (19%) ex-
hibited a positive result for  aacA - aphD  (involved in resis-
tance to gentamicin and tobramycin), 3 isolates (5%) for 
 addD  (conferring resistance to tobramycin and neomy-
cin), and 1 isolate (2%) for  aphA (involved in resistance 
to kanamycin and neomycin). The resistance gene  dfrA 
(conferring resistance to trimethoprim) was found in 5 
isolates (9%). In none of the  S. aureus isolates, resistance 
genes for other agents, including genes conferring resis-
tance to vancomycin, teicoplanin, linezolid, or mupiro-
cin, were found. Concerning the detected virulence genes, 
a wide variety of genes encoding superantigens, including 
toxic shock syndrome toxin, major enterotoxins, and ex-
foliate toxins, were detected, as well as various haemoly-
sins, leukocidins, and adhesins (online suppl. table  2). 
 Table 1.  Antimicrobial resistance phenotypes of 58 S. aureus 
isolates collected from CF patients in Austria
n (%)  Antimicrobial agents
OX  P ERY CLI G TM
22 (38) – X – – – –
14 (24) – X X (X)a – –
8 (14) – – – – – –
3 (5) – X – – X X
2 (3) – X X – – –
1 (2) – – X (X)a – –
1 (2) – X X – – –
1 (2) – X – – – X
1 (2) – X X – X –
1 (2) – X X (X)a – X
1 (2) – X X (X)a X X
1 (2) X X X X – –
1 (2) – X X X X X
1 (2) X X X (X)a – X
Total, n 2 49 21 2 (18)a 6 8
Total, % 3 84 41 3 (31)a (10) 14
 OX = Oxacillin; P = penicillin; ERY = erythromycin; CLI = 
clindamycin; G = gentamicin; TM = trimethoprim.
a Inducible clindamycin resistance
 Fig. 1. Genotypes and assignment to clonal complexes of 58  S. au-
reus isolates from CF patients from Austria. Distribution: CC30 
(13 isolates), CC15 (9 isolates), CC45 (8 isolates), CC5 (7 isolates), 
CC22 (4 isolates), CC398 (3 isolates), and CC8, CC9, and CC121 
(2 isolates each). The unlabeled minor isolates were CC1, CC6, 
CC7, CC25, CC25/28, CC101, and CC152 with 1 isolate each, and 
there was 1 not assignable isolate. 
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The gene coding for the pore-forming exotoxin Panton-
Valentine leukocidin (PVL) could not be detected in any 
of the isolates. Assignment to  agr types showed the fol-
lowing distribution: 27 isolates (47%) belonged to  agr I, 
18 (31%) to  agr II, 15 (26%) to  agr III, and 10 (17%) to  agr 
IV. A comprehensive list of all microarray results, includ-
ing genes encoding haemolysins, leukocidins, adhesins, 
as well as proteins involved in immune evasion, is pro-
vided in the supplementary material.
 Discussion 
 Within the last years, several studies have reported a 
dramatic increase in MRSA strains isolated from CF pa-
tients, with MRSA rates of up to 25%  [4] . While for many 
decades, MRSA was solely associated with health care-
associated transmission and infections, so-called com-
munity-acquired MRSA (CA-MRSA) can now be found 
both in the community but also in the hospital setting  [5, 
6] . It has been controversially discussed if the increase in 
CA-MRSA, which frequently carry PVL ,  represents a new 
threat to CF patients  [14, 15] . PVL has been epidemio-
logically associated with severe skin and soft tissue infec-
tions, up to necrotizing pneumonia or severe sepsis  [16] .
 In this study, MRSA could be detected in only 2 pa-
tients (3%), and none of the investigated strains was pos-
itive for PVL. A similar result was also reported by Cam-
pana et al.  [14] who investigated MRSA isolates from 9 
Italian CF centres. The MRSA isolate carrying SCC mec V 
was assigned to CC152/t355, which was recently detected 
among CA-MRSA in Austria  [17, 18] . The MRSA isolate 
carrying SCC mec I was assigned to CC5/t001, which was 
reported in association with a hospital-acquired MRSA 
lineage (presumed Southern Germany clone)  [19] . The 
overall low percentage of MRSA detected in our study is 
in accordance with previous reports describing constant-
ly low local MRSA rates  [17] . In addition, the CF centre 
 Fig. 2. SplitsTree depicting similarity of re-
sistance and virulence gene profiles deter-
mined by DNA microarray for 58  S. aureus 
isolates from CF patients in Austria. Clon-
al complexes are indicated for clusters 
comprised of 3 or more isolates. The 2 
MRSA isolates are marked by black circles. 
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at which the samples were collected follows a strict hy-
giene regimen to avoid person-to-person transmission. 
This includes single rooms for inpatients, as well as a 
strict separation of outpatients with known colonization 
with  Pseudomonas spp ., Burkholderia spp., MRSA, and 
nontuberculous mycobacteria. It is conceivable that the 
fact that each  S. aureus  strain was found only once among 
CF patients in our study is at least partly due to this strict 
hygiene regimen.
 We did not only detect MRSA but also a multitude of 
strains  resistant to penicillin, erythromycin, clindamycin, 
gentamicin, and trimethoprim. Only 14% of the isolates 
in this study were susceptible to all tested antimicrobial 
agents. The high rate of resistant strains mirrors a high 
selective pressure due to the antibiotic regimens that were 
used to treat CF patients. In the local CF centre, prophy-
lactic flucloxacillin to prevent infection with  S. aureus or 
chronic maintenance therapy with oral antistaphylococ-
cal antibiotics are not used, in accordance with current 
guidelines  [20] . However, as in many other CF centres 
and in line with agreed treatment standards, maintenance 
therapy with azithromycin was used in a number of pa-
tients chronically infected with  Pseudomonas aeruginosa 
due to the dual effect of macrolides on infection and in-
flammation, despite concerns regarding the induction of 
resistance. In addition, it is standard to recommend the 
use of amoxicillin/clavulanic acid or other antistaphylo-
coccal antibiotics (e.g. flucloxacillin) for a minimum of 2 
weeks in case of viral respiratory tract infections, and for 
at least 4 weeks with pulmonary exacerbations if  S. aureus 
is suspected to be the cause of the exacerbation. When a 
patient with pulmonary exacerbation has to be admitted 
for intravenous antibiotic therapy and  S. aureus is iso-
lated, an antistaphylococcal antibiotic is added to the 
treatment regimen.
 The 58  S. aureus  strains investigated in this study were 
assigned to a wide variety of clonal complexes and  spa 
 types and exhibited pronounced diversity regarding re-
sistance and virulence gene profiles. All clonal complexes 
detected in this study can be commonly found among  S. 
aureus strains  isolated from humans colonized or infect-
ed with  S. aureus  [13, 21, 22] . Furthermore, there is evi-
dence that the main reservoir of the  S. aureus isolates is 
not the clinical setting, due to the predominance of MLST 
CC30 and CC15, described as community-associated  S. 
aureus  [23] .
 There are reports that after the first acquisition of  S. 
aureus , these isolates persist for a longer period. In a study 
by Hirschhausen et al.  [24] , long-term persistence of >5 
years with the same individual and isogenic  S. aureus 
strain was detected. In vivo adaption processes could be 
observed, but the adaption processes seem to be very 
complex and might be influenced by individual host fac-
tors.
 Some limitations of the study have to be addressed. 
While knowing the local antibiotic regimen, for this 
study, no detailed information on the antibiotic therapy 
of each individual CF patient or the clinical status at the 
day of sampling was retrieved. Beside that, this study was 
conducted in only a single CF centre in Austria and might 
be influenced by geographic or epidemiological factors. 
However, based on the fact that the same individual  S. 
aureus strain might continuously colonize a CF patient, 
further studies could focus on the impact of these micro-
biological findings concerning the clinical status in these 
patients.
 Conclusions 
 To conclude, this study provides for the first time in-
formation on the genomic background of  S. aureus strains 
isolated from CF patients in Austria. In contrast to the 
high prevalence of MRSA reported among  S. aureus  iso-
lates from CF patients in the US, only few MRSA isolates 
were detected (3%). The  S. aureus  isolates investigated in 
this study exhibited high genetic diversity with regard to 
clonal complexes,  spa types, as well as resistance and vir-
ulence gene profiles. This indicates that acquisition of 
these strains more likely occurred in the community set-
ting than by patient-to-patient transmission.
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